Proactive Investors - Run By Investors For Investors

Sareum's Tim Mitchell looks ahead to critical Phase II data from flagship Chk1 inhibitor

Sareum Holdings Plc (LON:SAR) CEO Tim Mitchell updates Proactive London's Andrew Scott on the progress being made by Sierra Oncology – its partner which is taking SRA737 through the clinic.

Sierra is currently using SRA737 in two early-stage ovarian cancer studies: one as a monotherapy and another in combination with low-dose gemcitabine – one of the most commonly-prescribed chemotherapies.

Preliminary data from these trials are expected within the next few months.

Sareum's also been investing a lot of time in its TYK2/JAK1 programme.

It has recently selected two molecules – one targeting autoimmune diseases and the other targeting certain types of leukaemia, lymphoma and solid tumours – for preclinical development.

 
Meet Cornish Lithium, Salt Lake Potash Ltd and Concepta at our event, London , 05 June 2019. Register here »
View full SAR profile View Profile

Sareum Holdings PLC Timeline

Big Picture
February 22 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use